+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
52.6000
1.7600
1.7600
High
null
No
No
No
No
No
No
null
5,7-Dimethoxycoumarins (Citropten, CAS No.: 487-06-9), as an important coumarin-derived derivative, have attracted widespread attention in the field of natural product pharmacology in recent years. Coumarins are widely studied for the treatment of anti-inflammatory, anti-cancer, antidepressant, and anticoagulant diseases due to their diverse bioactivities and excellent pharmacological properties. 5,7-Dimethoxycoumarin, as a representative molecule, exhibits significant anti-melanoma cell proliferation, anti-inflammatory, and antidepressant multiple pharmacological activities. Its mechanism of action involves multiple signaling pathways and molecular targets, including NF-κB, MAPK, heat shock protein-70 (HSP70), and monoamine oxidase A (MAOA), demonstrating its potential therapeutic value across various diseases.
This paper aims to systematically review the chemical structure and physicochemical properties, plant origin and extraction methods, pharmacological activity and mechanism of action of 5,7-dimethoxycoumarin, druggability evaluation, and pharmacokinetic characteristics, while also exploring its clinical application prospects and development trends, providing theoretical basis and reference for in-depth research and drug development of this natural product.
5,7-Dimethoxycoumarin, a typical coumarin, has a molecular formula of C11H10O4 and a molecular weight of 206.19. Its structural feature is that two methoxy (-OCH3) substituents are attached at positions 5 and 7 of the coumarin's core backbone. This structure imparts a certain degree of hydrophobicity and electron cloud distribution, affecting its biological activity and pharmacokinetic properties.
In terms of physicochemical properties, the LogP value of 5,7-dimethoxycoumarins is 1.76, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and bioavailability. Its topological pole surface area (TPSA) is 52.6 Ų, and it has 4 hydrogen bond acceptors, suggesting that its molecules have moderate polarity, which may affect their ability to bind to biological macromolecules. This compound can efficiently cross the blood-brain barrier (BBB), offering possibilities for its application in central nervous system diseases. Additionally, 5,7-dimethoxycoumarin, which has no hepatotoxicity, cardiotoxicity, or hERG channel inhibitory effects, and the Ames-induced mutagenic test results were negative, indicating high safety and promising drug potential.
5,7-Dimethoxycoumarin, widely found in the peel and leaves of Citrus spp., especially in common fruits such as lemons, oranges, and grapefruits, is found in high concentrations. Its naturally occurring form is mostly in free or bound form, and it often coexists with other coumarins and flavonoid compounds.
Traditional extraction methods mainly use organic solvent extraction methods, with commonly used solvents including ethanol, methanol, and ethyl acetate. The extraction process typically includes drying and crushing plant materials, solvent soaking, ultrasound-assisted extraction or reflux extraction, followed by purification through liquid-liquid partitioning and column chromatography. In recent years, supercritical CO2 extraction and microwave-assisted extraction technologies have also been applied to improve extraction efficiency and purity, reduce solvent usage, and align with the concept of green chemistry.
Purified 5,7-dimethoxycoumarins can be identified and content determined using techniques such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) to ensure the stability of its quality and active components.
5,7-Dimethoxycoumarins exhibited significant anti-proliferative effects on various cancer cells, especially demonstrating good cytotoxicity in melanoma cell lines A2058 and B16. Its anti-cancer mechanism mainly works by inducing cell cycle arrest, promoting apoptosis, and inhibiting tumor cell migration and invasion. Related studies have shown that this compound can regulate BRAF protein and downstream MAPK signaling pathways, inhibiting tumor cell proliferation and survival.
5,7-Dimethoxycoumarins exhibit significant anti-inflammatory activity across various inflammation models. Its mechanism involves inhibiting the signaling pathways of nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK), reducing the expression of pro-inflammatory factors such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2/PTGS2), thereby alleviating inflammatory responses. This compound also demonstrated good efficacy in lung inflammatory disease models, suggesting its potential application value in respiratory inflammatory diseases.
5,7-Dimethoxycoumarins exert antidepressant effects by regulating key targets such as heat shock protein-70 (HSP70), monoamine oxidase A (MAOA), and 5-hydroxytryptamine transporter protein (SLC6A4). Its mechanisms may involve neuroprotection, regulation of neurotransmitter metabolism, inhibition of apoptosis, promotion of brain-derived neurotrophic factor (BDNF) expression, and enhancement of neuroplasticity. Additionally, this compound also regulates the glutamate receptor (GRIN1), further supporting its antidepressant potential.
Although research on the anticoagulant effects of 5,7-dimethoxycoumarins is relatively limited, its potential interactions with targets such as coagulation factors F2, F7, F9, F10, and vitamin K epoxyreductase complex 1 (VKORC1) suggest its potential to regulate blood coagulation, providing a theoretical basis for adjunctive therapy of thrombotic diseases.
The multiple pharmacological activities of 5,7-dimethoxycoumarins depend on its regulation of multiple signaling pathways and key targets:
NF-κB signaling pathway: As an important regulatory factor of inflammation and tumorigenesis, inhibition of NF-κB is one of the core mechanisms of 5,7-dimethoxycoumarin's anti-inflammatory and anticancer effects. This compound blocks NF-κB nuclear translocation by inhibiting IκB kinase activity, reducing the expression of pro-inflammatory genes.
MAPK signaling pathway: 5,7-Dimethoxycoumarin, which regulates the activities of ERK, JNK, and p38 MAPK subtypes, affecting cell proliferation, apoptosis, and inflammatory responses, especially prominent in melanoma cells and inflammation models.
Heat shock protein-70 (HSP70): This protein plays a key role in cellular stress responses and neuroprotection. 5,7-Dimethoxycoumarin, by upregulating HSP70 expression, enhances cellular resilience, and exerts antidepressant and protective effects.
Monoamine Oxidase A (MAOA): As a key enzyme in neurotransmitter metabolism, inhibition of MAOA helps increase levels of monoamine neurotransmitters in the brain and alleviates depressive symptoms. 5,7-Dimethoxycoumarin's regulation of MAOA provides a molecular basis for its antidepressant effects.
BRAF protein: 5,7-Dimethoxycoumarin, can intervene in BRAF kinase activity, block its downstream MAPK signaling pathway, and inhibit abnormal proliferation of melanoma cells.
Other targets include cytochrome P450 1A1 (CYP1A1), serotonin 5-hydroxytryptamine transporter (SLC6A4), brain-derived neurotrophic factor (BDNF), and glutamate receptor (GRIN1), all involved in multidimensional pharmacological regulation.
5,7-Dimethoxycoumarins have good druggability indicators. Its molecular weight is moderate, the LogP value is suitable for cell membrane permeability, and the TPSA and hydrogen bond receptor counts fall within the ideal range for oral drug absorption. Its high blood-brain barrier penetration gives it an advantage in treating central nervous system diseases. In terms of safety, there is no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and the Ames test is negative, reducing the risk of potential toxic side effects.
Pharmacokinetic studies show that 5,7-dimethoxycoumarin, after oral administration, is well absorbed, widely distributed in the body, and is especially enriched in brain tissue. Its metabolic pathway mainly occurs through the hepatic cytochrome P450 enzyme system, with relatively stable metabolites. Excretion mainly occurs through urine and bile. Its moderate half-life supports its development as an oral drug.
Based on the diverse activities of 5,7-dimethoxycoumarin, including anticancer, anti-inflammatory, antidepressant, and anticoagulant effects, its clinical application prospects are broad. Especially in adjuvant therapy for malignant tumors such as melanoma, 5,7-dimethoxycoumarins are expected to serve as novel small-molecule drugs or combination drug components, enhancing treatment outcomes and reducing chemotherapy side effects. In inflammatory diseases and pulmonary inflammatory diseases, its role in inhibiting key inflammatory signaling pathways offers new strategies for intervention in both chronic and acute inflammation.
Additionally, 5,7-Dimethoxycoumarin's excellent blood-brain barrier penetration and neuroprotective effects give it potential application value in the treatment of depression and other neuropsychiatric disorders. In the future, structural optimization and dosage form improvements can enhance its bioavailability and targeting.
However, clinical research on 5,7-dimethoxycoumarins is still in its early stages, urgently requiring systematic clinical trials on pharmacodynamics, safety, and pharmacokinetics to verify its efficacy and safety. At the same time, in-depth analysis of its molecular mechanisms and optimized extraction and purification processes will lay a solid foundation for its drug development.
5,7-Dimethoxycoumarin, as a natural coumarin-derived with multiple pharmacological activities, demonstrates potential in anti-cancer, anti-inflammatory, antidepressant, and anticoagulant fields. Its excellent druggability and safety provide strong support for clinical translation. In the future, through multidisciplinary research combined with modern medicinal chemistry, molecular biology, and clinical medical approaches, the mechanism of action of 5,7-dimethoxycoumarin, along with optimization of its medicinal properties, will promote it to become an important representative of new natural medicines and benefit a wide range of patients.
Shenshuai
Wenjing
Hedandan
